The Global Initiative for Asthma (GINA) is an independent organization established by the WHO and NHLBI in 1993 to increase awareness of asthma and improve asthma prevention and management worldwide through coordinated efforts. GINA publishes annual evidence-based strategy reports that provide practical guidance on asthma diagnosis and treatment, which have been downloaded over 500,000 times from 100 countries. The 2022 report includes updates to the diagnostic algorithm for asthma and treatment guidelines, such as emphasizing low-dose ICS-formoterol as the preferred reliever medication option.
This document summarizes key points from a presentation on asthma. It discusses the definition, epidemiology, pathophysiology, diagnosis, management, and severe asthma. Some key points include:
- Asthma is a chronic airway disease characterized by reversible airflow limitations and variable symptoms.
- It affects over 300 million people worldwide and prevalence has risen in affluent countries over the past 30 years.
- Asthma involves chronic inflammation of the lower airways. Diagnosis is based on symptoms and variable expiratory airflow limitation.
- Management involves a stepwise approach starting with reliever medications and adding controller medications as needed.
The GINA report provides an evidence-based global strategy for asthma management and prevention. In 2019, GINA made landmark changes including no longer recommending short-acting beta agonist (SABA)-only treatment and recommending that all adults and adolescents with asthma receive low-dose inhaled corticosteroid (ICS)-containing controller treatment to reduce exacerbation risk. This decision was based on evidence that SABA-only treatment increases exacerbation risk, while ICS significantly reduces this risk. GINA also updated its treatment steps figure to reflect these changes.
This document outlines guidelines for the management of asthma in children. It discusses definitions of asthma, risk factors, pathogenesis, assessment and diagnosis, investigations including spirometry and peak expiratory flow rates, pharmacological and non-pharmacological management, management in primary care settings and when to refer to specialists. It also provides a step-by-step approach to asthma treatment and medication options based on symptom control.
1. The document outlines the GINA treatment steps for asthma management, which involve a stepwise approach to treatment based on asthma severity and control.
2. It begins with Step 1 involving use of a short-acting beta 2 agonist as needed and considers adding regular low-dose inhaled corticosteroids.
3. Steps then involve adding controllers as symptoms are not well controlled, such as low-dose inhaled corticosteroids and long-acting beta 2 agonists in Step 2, and medium-dose controllers in Steps 3 and 4. Step 5 involves referral to specialist care for add-on treatments.
This document summarizes some of the key changes in the 2017 versions of GINA (Global Initiative for Asthma) and GOLD (Global Strategy for Diagnosis, Management and Prevention of COPD). It discusses updates to the definitions of asthma and its diagnosis. The stepwise approach to asthma management has been updated, including adding sublingual immunotherapy as an optional add-on treatment for some adult patients. Other changes include guidance on stepping down treatment and side effects of oral corticosteroids.
The Global Initiative for Asthma (GINA) was established in 1993 to increase awareness of asthma worldwide and improve management through coordinated efforts. GINA annually publishes evidence-based guidelines focusing on clinical practice translation. Asthma is a heterogeneous disease typically involving chronic airway inflammation and variable airflow limitation. Many clinical phenotypes exist, including allergic, non-allergic, adult-onset, obesity-related, and persistent airflow limitation asthma. GINA recommends control-based management using both controller medications to reduce inflammation and future risks, and reliever medications for symptom relief. Treatment is adjusted based on asthma control assessment.
This document summarizes key points from a presentation on asthma. It discusses the definition, epidemiology, pathophysiology, diagnosis, management, and severe asthma. Some key points include:
- Asthma is a chronic airway disease characterized by reversible airflow limitations and variable symptoms.
- It affects over 300 million people worldwide and prevalence has risen in affluent countries over the past 30 years.
- Asthma involves chronic inflammation of the lower airways. Diagnosis is based on symptoms and variable expiratory airflow limitation.
- Management involves a stepwise approach starting with reliever medications and adding controller medications as needed.
The GINA report provides an evidence-based global strategy for asthma management and prevention. In 2019, GINA made landmark changes including no longer recommending short-acting beta agonist (SABA)-only treatment and recommending that all adults and adolescents with asthma receive low-dose inhaled corticosteroid (ICS)-containing controller treatment to reduce exacerbation risk. This decision was based on evidence that SABA-only treatment increases exacerbation risk, while ICS significantly reduces this risk. GINA also updated its treatment steps figure to reflect these changes.
This document outlines guidelines for the management of asthma in children. It discusses definitions of asthma, risk factors, pathogenesis, assessment and diagnosis, investigations including spirometry and peak expiratory flow rates, pharmacological and non-pharmacological management, management in primary care settings and when to refer to specialists. It also provides a step-by-step approach to asthma treatment and medication options based on symptom control.
1. The document outlines the GINA treatment steps for asthma management, which involve a stepwise approach to treatment based on asthma severity and control.
2. It begins with Step 1 involving use of a short-acting beta 2 agonist as needed and considers adding regular low-dose inhaled corticosteroids.
3. Steps then involve adding controllers as symptoms are not well controlled, such as low-dose inhaled corticosteroids and long-acting beta 2 agonists in Step 2, and medium-dose controllers in Steps 3 and 4. Step 5 involves referral to specialist care for add-on treatments.
This document summarizes some of the key changes in the 2017 versions of GINA (Global Initiative for Asthma) and GOLD (Global Strategy for Diagnosis, Management and Prevention of COPD). It discusses updates to the definitions of asthma and its diagnosis. The stepwise approach to asthma management has been updated, including adding sublingual immunotherapy as an optional add-on treatment for some adult patients. Other changes include guidance on stepping down treatment and side effects of oral corticosteroids.
The Global Initiative for Asthma (GINA) was established in 1993 to increase awareness of asthma worldwide and improve management through coordinated efforts. GINA annually publishes evidence-based guidelines focusing on clinical practice translation. Asthma is a heterogeneous disease typically involving chronic airway inflammation and variable airflow limitation. Many clinical phenotypes exist, including allergic, non-allergic, adult-onset, obesity-related, and persistent airflow limitation asthma. GINA recommends control-based management using both controller medications to reduce inflammation and future risks, and reliever medications for symptom relief. Treatment is adjusted based on asthma control assessment.
This document summarizes treatment strategies for asthma according to guidelines from GINA (Global Initiative for Asthma). It outlines two treatment tracks, one using low-dose ICS-formoterol as both maintenance and reliever therapy (Track 1), and one using separate controllers and SABA relievers (Track 2). Treatment is adjusted in a stepwise manner based on asthma control. The goal is personalized asthma management through ongoing assessment, adjustment, and review of symptoms, exacerbations, lung function, adherence, and patient preferences/goals.
Updates on Pharmaological Management of Asthma & COPDAshraf ElAdawy
This document discusses updates to guidelines for pharmacological management of asthma and COPD. It provides:
1) A brief history of major asthma guidelines published since 1989 by expert panels and the Global Initiative for Asthma (GINA).
2) Overviews of asthma pathophysiology, definitions, and goals of therapy focused on reducing impairment and risk.
3) Descriptions of controller and reliever medications for asthma, including inhaled corticosteroids, long-acting beta agonists, leukotriene modifiers, theophylline, and biologics.
4) Details on the GINA treatment steps and assessments of asthma control and symptom control.
5) Guidance on proper inhal
Stepwise Approach For Adjusting Asthma Treatment 2017 Ashraf ElAdawy
The document discusses asthma control and management. It provides tools for assessing asthma control, such as the Asthma Control Test. It identifies risk factors for exacerbations and poor outcomes. It also outlines the stepwise approach to asthma management, with Steps 1 through 5 representing increasing treatment intensity. Initial treatment is usually with a low-dose inhaled corticosteroid, but may be at a higher step depending on symptom frequency and risk factors. The preferred option for Step 3 treatment in children ages 6-11 is a medium-dose inhaled corticosteroid, while options for adults include increasing the corticosteroid dose or adding a long-acting beta-2 agonist or other controller.
The document summarizes the 2019 Global Initiative for Asthma (GINA) guidelines. Key changes from prior years include: (1) short-acting beta agonists alone are no longer recommended for initial treatment due to increased risk of severe exacerbations; (2) all adults and adolescents should receive low-dose inhaled corticosteroids to reduce exacerbation risk. The guidelines outline criteria for diagnosing asthma, assessing patients, developing treatment plans, adjusting medications based on control, and managing exacerbations. The overall goals of treatment are to reduce risks of death, exacerbations, airway damage and medication side effects.
Guideline approaches to initial asthma therapy in adolescents and adults.pdfhamid15abass
This document summarizes the guideline recommendations from the National Asthma Education and Prevention Program and the Global Initiative for Asthma for initial asthma therapy in adolescents and adults. It outlines 5 steps of increasing treatment intensity based on asthma symptoms and lung function. For each step it provides options for daily controller medications and quick-relief medications. The recommendations are meant for newly diagnosed patients or those using only quick-relief medications.
Bronchial Asthma Management in Children GINA UpdatesShubhamPandit60
This document provides guidelines for the treatment and management of bronchial asthma. It discusses assessing asthma severity and control, patient education, controlling exacerbating factors, and pharmacological therapy. The key changes in GINA'23 include assessing asthma severity retrospectively based on treatment required for control rather than difficulty to treat. It emphasizes using the lowest effective maintenance treatment and adjusting therapy through a continual cycle based on periodic assessment and review.
The document provides an overview of the Global Initiative for Asthma's 2019 strategy for asthma management and prevention. It discusses GINA's goals of reducing asthma prevalence, morbidity, and mortality. It also summarizes the key aspects of asthma including phenotypes, diagnosis, assessment of control and risk factors, and pharmacological and non-pharmacological treatment strategies. The treatment approach involves classifying asthma severity and control to determine the appropriate controller medications and adjusting the treatment regimen up or down as needed.
The document summarizes the Global Initiative for Asthma's 2019 strategy for managing asthma. It outlines that asthma is a heterogeneous disease characterized by chronic airway inflammation. It then discusses asthma phenotypes, diagnosis of asthma, assessing asthma control and risk factors, and treatment options. The treatment approach involves a stepwise approach starting with low dose inhaled corticosteroids and adding additional controllers as needed to control symptoms and reduce exacerbation risk. The 2019 update emphasizes adding inhaled corticosteroids for all patients rather than short-acting bronchodilators alone due to risks of exacerbations from the latter approach.
The Novel START trial found that among patients with mild asthma, using budesonide-formoterol as needed significantly reduced the risk of asthma exacerbations compared to using albuterol as needed. It also showed a lower exacerbation rate than the budesonide maintenance group, though the difference was not statistically significant. Based on these results, the 2022 GINA guidelines were updated to recommend using budesonide-formoterol as needed as the preferred treatment approach for mild asthma. Budesonide-formoterol is currently available as a hydrofluoroalkane inhaler in two strengths.
Dr. Kumar Utsav presented an update on the Global Initiative for Asthma (GINA) 2017 guidelines. Key changes included adding sublingual immunotherapy as an add-on option for some patients, updating recommendations for severe asthma treatment including new biologics, and clarifying the use of fractional exhaled nitric oxide testing in diagnosis and management. The guidelines emphasize a practical clinical approach for managing asthma in both high and low-resource settings.
GINA GUIDELINES LONGTERM MANAGEMENT OF ASTHMA.pdfmadhurikakarnati
This document provides guidance on the long-term management of asthma in children and adults. It discusses:
- Inhaled corticosteroids as the mainstay of daily treatment, with short-acting beta agonists for relief of symptoms. Dosages depend on age and severity.
- For some children over 6, the addition of long-acting beta agonists. Children over 12 need adult dosages.
- Metered dose inhalers with spacers are preferred for all children. Montelukast has a limited role and there are warnings about its long-term use.
- Treatment is stepped up or down based on symptom control and future risk of exacerbations. Regular assessment and adjustment of the treatment
ast ma bronchial vb .pptx bronchial asthmaSaurav Jangir
This document provides an overview of the Global Initiative for Asthma (GINA) 2015 update. It discusses the structure and goals of GINA, which aims to provide an evidence-based global strategy for asthma management and prevention. The document reviews key changes in the 2015 GINA update, including revisions to the definitions of asthma and asthma control. It also summarizes GINA's approach to assessing evidence and provides slides on the diagnosis and treatment of asthma.
Act training 15 aug 2011 m sills editsMarion Sills
Educational materials (slide-set and accompanying script) used to train-the-trainers in SAFTINet practices on incorporating the Asthma Control Test into their clinical workflow and decision-making for patients with asthma.
For more information on SAFTINet, please see http://www.ucdenver.edu/academics/colleges/medicalschool/programs/outcomes/COHO/saftinet/Pages/default.aspx
This document discusses asthma and COPD, including key differences and updates. It provides an overview of asthma, describing it as a chronic inflammatory airway disorder characterized by recurrent wheezing, breathlessness, and coughing. It also provides an overview of COPD, describing it as a common lung disease associated with exposure to noxious particles or gases. The document reviews epidemiology, pathophysiology, diagnosis, management, and updates from the GINA and GOLD guidelines for both conditions.
Asthma is a chronic disease characterized by airway inflammation and intermittent airflow obstruction. It affects over 300 million people worldwide and can impact quality of life and work productivity if not well-controlled. The diagnosis of asthma involves a history of respiratory symptoms that vary over time and intensity, along with evidence of variable expiratory airflow limitation. Treatment aims to control symptoms and reduce future risk of exacerbations through a stepwise treatment approach using inhaled corticosteroids and bronchodilators, along with patient education on self-management including the use of written asthma action plans.
1. The document discusses asthma, including its definition as a chronic inflammatory airway disease characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm.
2. It provides guidelines for diagnosing and treating asthma, including a stepwise approach for treatment based on symptom severity. Initial treatment involves inhaled corticosteroids with escalation to additional controllers as needed.
3. Risk factors that can lead to worse asthma outcomes like exacerbations or persistent airflow limitation are also discussed. These include poor adherence, smoking, obesity, allergies, and comorbidities.
GINA 2019: a fundamental change in asthma management Ashraf ElAdawy
Mild asthma accounts for 50-75% of the asthma population. While symptoms may be infrequent or mild, airway inflammation is still present and patients are at risk of exacerbations. Recent guidelines recommend low-dose inhaled corticosteroids as the preferred first-line treatment for mild asthma over short-acting beta agonists alone due to safety concerns around overreliance on reliever medications and risk of exacerbations. New studies provide evidence that symptom-driven use of combination inhalers containing an inhaled corticosteroid and long-acting beta agonist may be effective alternatives to regular maintenance treatment for mild asthma.
The document summarizes key changes and recommendations from the 2015 Global Initiative for Asthma (GINA) update, including:
- Add-on tiotropium by soft-mist inhaler is a new treatment option for Steps 4 and 5 in patients ≥18 years with exacerbation history.
- Management of asthma in pregnancy includes monitoring for infections and using usual controllers during labor/delivery.
- Dry powder inhalers can deliver SABA in mild-moderate exacerbations but not for severe acute asthma.
- For life-threatening asthma in primary care, give SABA, ipratropium, systemic corticosteroids, and oxygen while arranging transfer.
Global Medical Cures™ | Asthma Care Quick Reference
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
This document summarizes treatment strategies for asthma according to guidelines from GINA (Global Initiative for Asthma). It outlines two treatment tracks, one using low-dose ICS-formoterol as both maintenance and reliever therapy (Track 1), and one using separate controllers and SABA relievers (Track 2). Treatment is adjusted in a stepwise manner based on asthma control. The goal is personalized asthma management through ongoing assessment, adjustment, and review of symptoms, exacerbations, lung function, adherence, and patient preferences/goals.
Updates on Pharmaological Management of Asthma & COPDAshraf ElAdawy
This document discusses updates to guidelines for pharmacological management of asthma and COPD. It provides:
1) A brief history of major asthma guidelines published since 1989 by expert panels and the Global Initiative for Asthma (GINA).
2) Overviews of asthma pathophysiology, definitions, and goals of therapy focused on reducing impairment and risk.
3) Descriptions of controller and reliever medications for asthma, including inhaled corticosteroids, long-acting beta agonists, leukotriene modifiers, theophylline, and biologics.
4) Details on the GINA treatment steps and assessments of asthma control and symptom control.
5) Guidance on proper inhal
Stepwise Approach For Adjusting Asthma Treatment 2017 Ashraf ElAdawy
The document discusses asthma control and management. It provides tools for assessing asthma control, such as the Asthma Control Test. It identifies risk factors for exacerbations and poor outcomes. It also outlines the stepwise approach to asthma management, with Steps 1 through 5 representing increasing treatment intensity. Initial treatment is usually with a low-dose inhaled corticosteroid, but may be at a higher step depending on symptom frequency and risk factors. The preferred option for Step 3 treatment in children ages 6-11 is a medium-dose inhaled corticosteroid, while options for adults include increasing the corticosteroid dose or adding a long-acting beta-2 agonist or other controller.
The document summarizes the 2019 Global Initiative for Asthma (GINA) guidelines. Key changes from prior years include: (1) short-acting beta agonists alone are no longer recommended for initial treatment due to increased risk of severe exacerbations; (2) all adults and adolescents should receive low-dose inhaled corticosteroids to reduce exacerbation risk. The guidelines outline criteria for diagnosing asthma, assessing patients, developing treatment plans, adjusting medications based on control, and managing exacerbations. The overall goals of treatment are to reduce risks of death, exacerbations, airway damage and medication side effects.
Guideline approaches to initial asthma therapy in adolescents and adults.pdfhamid15abass
This document summarizes the guideline recommendations from the National Asthma Education and Prevention Program and the Global Initiative for Asthma for initial asthma therapy in adolescents and adults. It outlines 5 steps of increasing treatment intensity based on asthma symptoms and lung function. For each step it provides options for daily controller medications and quick-relief medications. The recommendations are meant for newly diagnosed patients or those using only quick-relief medications.
Bronchial Asthma Management in Children GINA UpdatesShubhamPandit60
This document provides guidelines for the treatment and management of bronchial asthma. It discusses assessing asthma severity and control, patient education, controlling exacerbating factors, and pharmacological therapy. The key changes in GINA'23 include assessing asthma severity retrospectively based on treatment required for control rather than difficulty to treat. It emphasizes using the lowest effective maintenance treatment and adjusting therapy through a continual cycle based on periodic assessment and review.
The document provides an overview of the Global Initiative for Asthma's 2019 strategy for asthma management and prevention. It discusses GINA's goals of reducing asthma prevalence, morbidity, and mortality. It also summarizes the key aspects of asthma including phenotypes, diagnosis, assessment of control and risk factors, and pharmacological and non-pharmacological treatment strategies. The treatment approach involves classifying asthma severity and control to determine the appropriate controller medications and adjusting the treatment regimen up or down as needed.
The document summarizes the Global Initiative for Asthma's 2019 strategy for managing asthma. It outlines that asthma is a heterogeneous disease characterized by chronic airway inflammation. It then discusses asthma phenotypes, diagnosis of asthma, assessing asthma control and risk factors, and treatment options. The treatment approach involves a stepwise approach starting with low dose inhaled corticosteroids and adding additional controllers as needed to control symptoms and reduce exacerbation risk. The 2019 update emphasizes adding inhaled corticosteroids for all patients rather than short-acting bronchodilators alone due to risks of exacerbations from the latter approach.
The Novel START trial found that among patients with mild asthma, using budesonide-formoterol as needed significantly reduced the risk of asthma exacerbations compared to using albuterol as needed. It also showed a lower exacerbation rate than the budesonide maintenance group, though the difference was not statistically significant. Based on these results, the 2022 GINA guidelines were updated to recommend using budesonide-formoterol as needed as the preferred treatment approach for mild asthma. Budesonide-formoterol is currently available as a hydrofluoroalkane inhaler in two strengths.
Dr. Kumar Utsav presented an update on the Global Initiative for Asthma (GINA) 2017 guidelines. Key changes included adding sublingual immunotherapy as an add-on option for some patients, updating recommendations for severe asthma treatment including new biologics, and clarifying the use of fractional exhaled nitric oxide testing in diagnosis and management. The guidelines emphasize a practical clinical approach for managing asthma in both high and low-resource settings.
GINA GUIDELINES LONGTERM MANAGEMENT OF ASTHMA.pdfmadhurikakarnati
This document provides guidance on the long-term management of asthma in children and adults. It discusses:
- Inhaled corticosteroids as the mainstay of daily treatment, with short-acting beta agonists for relief of symptoms. Dosages depend on age and severity.
- For some children over 6, the addition of long-acting beta agonists. Children over 12 need adult dosages.
- Metered dose inhalers with spacers are preferred for all children. Montelukast has a limited role and there are warnings about its long-term use.
- Treatment is stepped up or down based on symptom control and future risk of exacerbations. Regular assessment and adjustment of the treatment
ast ma bronchial vb .pptx bronchial asthmaSaurav Jangir
This document provides an overview of the Global Initiative for Asthma (GINA) 2015 update. It discusses the structure and goals of GINA, which aims to provide an evidence-based global strategy for asthma management and prevention. The document reviews key changes in the 2015 GINA update, including revisions to the definitions of asthma and asthma control. It also summarizes GINA's approach to assessing evidence and provides slides on the diagnosis and treatment of asthma.
Act training 15 aug 2011 m sills editsMarion Sills
Educational materials (slide-set and accompanying script) used to train-the-trainers in SAFTINet practices on incorporating the Asthma Control Test into their clinical workflow and decision-making for patients with asthma.
For more information on SAFTINet, please see http://www.ucdenver.edu/academics/colleges/medicalschool/programs/outcomes/COHO/saftinet/Pages/default.aspx
This document discusses asthma and COPD, including key differences and updates. It provides an overview of asthma, describing it as a chronic inflammatory airway disorder characterized by recurrent wheezing, breathlessness, and coughing. It also provides an overview of COPD, describing it as a common lung disease associated with exposure to noxious particles or gases. The document reviews epidemiology, pathophysiology, diagnosis, management, and updates from the GINA and GOLD guidelines for both conditions.
Asthma is a chronic disease characterized by airway inflammation and intermittent airflow obstruction. It affects over 300 million people worldwide and can impact quality of life and work productivity if not well-controlled. The diagnosis of asthma involves a history of respiratory symptoms that vary over time and intensity, along with evidence of variable expiratory airflow limitation. Treatment aims to control symptoms and reduce future risk of exacerbations through a stepwise treatment approach using inhaled corticosteroids and bronchodilators, along with patient education on self-management including the use of written asthma action plans.
1. The document discusses asthma, including its definition as a chronic inflammatory airway disease characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm.
2. It provides guidelines for diagnosing and treating asthma, including a stepwise approach for treatment based on symptom severity. Initial treatment involves inhaled corticosteroids with escalation to additional controllers as needed.
3. Risk factors that can lead to worse asthma outcomes like exacerbations or persistent airflow limitation are also discussed. These include poor adherence, smoking, obesity, allergies, and comorbidities.
GINA 2019: a fundamental change in asthma management Ashraf ElAdawy
Mild asthma accounts for 50-75% of the asthma population. While symptoms may be infrequent or mild, airway inflammation is still present and patients are at risk of exacerbations. Recent guidelines recommend low-dose inhaled corticosteroids as the preferred first-line treatment for mild asthma over short-acting beta agonists alone due to safety concerns around overreliance on reliever medications and risk of exacerbations. New studies provide evidence that symptom-driven use of combination inhalers containing an inhaled corticosteroid and long-acting beta agonist may be effective alternatives to regular maintenance treatment for mild asthma.
The document summarizes key changes and recommendations from the 2015 Global Initiative for Asthma (GINA) update, including:
- Add-on tiotropium by soft-mist inhaler is a new treatment option for Steps 4 and 5 in patients ≥18 years with exacerbation history.
- Management of asthma in pregnancy includes monitoring for infections and using usual controllers during labor/delivery.
- Dry powder inhalers can deliver SABA in mild-moderate exacerbations but not for severe acute asthma.
- For life-threatening asthma in primary care, give SABA, ipratropium, systemic corticosteroids, and oxygen while arranging transfer.
Global Medical Cures™ | Asthma Care Quick Reference
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
Este documento define el parto pretérmino y sus complicaciones. Ocurre entre las 28 y 36 semanas de gestación y su incidencia es del 10-15% de los nacimientos. Es la principal causa de morbilidad y mortalidad neonatal. A pesar de los avances médicos, su prevalencia no ha cambiado. Las complicaciones incluyen problemas respiratorios, hemorragias cerebrales y sepsis. El diagnóstico, prevención y tratamiento son complejos con altas tasas de falsos positivos.
El documento introduce las dietas hospitalarias y la importancia de la pirámide alimenticia para guiar el diseño de planes de alimentación equilibrados para los pacientes. La pirámide alimenticia representa visualmente los grupos de alimentos recomendados y sus proporciones para una dieta saludable. Las dietas hospitalarias basadas en la pirámide alimenticia ayudan a satisfacer las necesidades nutricionales específicas de los pacientes y contribuyen a una recuperación más rápida mediante la nutrición equilibrada.
El documento introduce las dietas hospitalarias y la importancia de la pirámide alimenticia para guiar el diseño de planes de alimentación equilibrados para los pacientes. La pirámide alimenticia representa visualmente los grupos de alimentos recomendados y sus proporciones para una dieta saludable. Las dietas hospitalarias basadas en la pirámide alimenticia ayudan a satisfacer las necesidades nutricionales específicas de los pacientes y contribuyen a una recuperación más rápida mediante la nutrición equilibrada.
El documento habla sobre diferentes escalas y scores utilizados para evaluar la gravedad y pronóstico en pacientes con traumatismos craneoencefálicos. Explica que la escala ICH evalúa la mortalidad en hemorragias intracerebrales traumáticas y no traumáticas, y la escala de Fisher predice el riesgo de vasoespasmo en hemorragias subaracnoideas no traumáticas. También describe otras escalas como la de Marshall y la de Glasgow que clasifican la gravedad del traumatismo craneoencefá
Patologias Cardiovasculares que requieren cuidados criticos (1).pdfEdison Maldonado
Este documento describe las patologías cardiovasculares que requieren cuidados críticos, incluido el shock. Describe el sistema cardiovascular y diferentes tipos de alteraciones como la hipotensión y hipertensión arterial. Luego explica conceptos clave relacionados con el shock como el suministro de oxígeno, consumo de oxígeno y extracción de oxígeno, y cómo estos procesos son fundamentales para evitar el fracaso orgánico.
Este documento describe el aborto espontáneo, sus definiciones, causas, clasificaciones, signos y síntomas, diagnóstico, tratamiento y complicaciones. También describe el embarazo ectópico y la mola hidatiforme, incluidas sus definiciones, tipos, factores de riesgo, signos y síntomas, diagnóstico y tratamiento.
El documento describe la anatomía del corazón y el mediastino. El corazón se encuentra en el mediastino y está compuesto de dos bombas, una derecha y una izquierda, cada una con una aurícula y un ventrículo. El ciclo cardíaco involucra la contracción y relajación coordinada de las cámaras cardíacas impulsadas por el sistema de conducción eléctrico del corazón.
El documento describe el sistema cardiovascular. Explica que está formado por el corazón, los vasos sanguíneos y los vasos linfáticos, y tiene la función de impulsar y transportar la sangre por todo el organismo. Describe la estructura del corazón, las diferentes capas de las paredes vasculares, y los tipos principales de vasos como arterias, venas, capilares y el sistema linfático.
Radiation-Exposed Patients Medical Center by Slidesgo.pptxEdison Maldonado
Radiation-exposed patients who visit the medical center are the subject of the document. The center sees many patients each month and performs thousands of transplants annually. It also has high numbers of total visitors monthly.
El documento describe la transmisión neuromuscular y el acoplamiento excitación-contracción en el músculo esquelético. Explica que la acetilcolina se libera de las terminaciones nerviosas y se une a receptores en la fibra muscular, abriendo canales iónicos y generando un potencial de acción. Los iones de calcio liberados del retículo sarcoplásmico producen la contracción muscular. También describe fármacos que afectan la transmisión neuromuscular.
Este documento presenta información sobre la semiología del tórax. Explica la anatomía del tórax y los diferentes planos de exploración. Describe las cuatro maniobras del examen físico del tórax: inspección, auscultación, palpación y percusión. Detalla los tipos de respiraciones, frecuencias respiratorias, formas del tórax y algunas patologías como neumonía y neumotórax.
El documento proporciona información sobre antibióticos y cambios farmacocinéticos durante el embarazo. Explica que los antibióticos destruyen o impiden el crecimiento de microorganismos sensibles. Durante el embarazo, la absorción y distribución de los antibióticos puede verse afectada, así como su metabolismo y eliminación. También describe la clasificación de la FDA de teratogenicidad de los fármacos y las categorías de riesgo para diferentes tipos de antibióticos durante el embarazo.
El documento presenta una actualización de 2022 de la Estrategia Global de GINA para el Asma. GINA es una iniciativa global para el asma establecida por la OMS y el NHLBI en 1993 para mejorar la prevención y el control del asma a través de un esfuerzo mundial coordinado. El informe de GINA se actualiza anualmente y proporciona una estrategia global basada en evidencia que se puede adaptar a los sistemas de salud locales.
Este documento proporciona información sobre diferentes métodos anticonceptivos, incluyendo anticonceptivos hormonales como la píldora y los inyectables, anticonceptivos de barrera como preservativos y el diafragma, anticonceptivos quirúrgicos como la vasectomía y la ligadura de trompas, y métodos anticonceptivos naturales. Explica cómo funcionan cada uno de estos métodos, sus ventajas, desventajas y contraindicaciones. El documento también brinda detalles sobre la efectividad de los diferentes anticonceptivos
This document provides instructions and resources for customizing a clinical case presentation template from Slidesgo. It includes slides on patient history, examination findings, diagnosis, treatment, and conclusions. Graphics and icons are provided that can be edited or replaced. Instructions explain how to credit Slidesgo, and that premium users have more flexible usage rights than free users. Resources include medical photos, illustrations, and infographics that can be resized or recolored.
El documento describe varios métodos para examinar el abdomen mediante palpación, incluyendo técnicas monomanuales y bimanuales para la palpación profunda del abdomen, la localización e identificación de puntos dolorosos en el abdomen como el punto de Murphy y el punto de McBurney, y métodos para examinar órganos abdominales específicos como el hígado, bazo, riñones, así como signos de ascitis.
Este documento presenta información sobre el examen físico abdominal. Describe la anatomía abdominal, los cuadrantes del abdomen, síntomas comunes, y proporciona detalles sobre cómo realizar la inspección, auscultación, percusión y palpación del abdomen de manera ordenada. El objetivo es estructurar una anamnesis gastroenterológica dirigida y realizar un examen físico abdominal completo.
Cardiovascular Diseases_ Arrhythmia by Slidesgo.pptxEdison Maldonado
This document provides a template for creating a presentation about cardiovascular diseases and arrhythmia. It includes sections on the disease, diagnosis, recommendations, pathology, treatment, and conclusions. Each section contains editable placeholder slides that can be customized with information about arrhythmia. The template also includes additional resources like fonts, colors, icons, images, and references that can be used in the presentation.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.